Fateme Babaha: Pleasure to Present A Novel FVIII Gene Therapy Enhancer at ISTH 2026
Fateme Babaha, PhD in Pathology and Molecular Medicine at Queen’s University, shared on LinkedIn:
”It was a pleasure to present my research at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris!
It had the opportunity to present my work, ‘Efficacy of AAV-mediated FVIII transgene expression employing a short enhancer element from the human F8 locus,’ and to connect with researchers and experts in the field of hemophilia and gene therapy.
In this study, we investigated a novel, compact 92-bp enhancer element from the human F8 locus and its potential to improve FVIII transgene expression for hemophilia A gene therapy.
I’m grateful to my supervisor Dr. David Lillicrap for his continued support and to everyone who stopped by my poster for the insightful discussions and questions.”
Stay updated with Hemostasis Today.
-
Sep 8, 2026, 16:14Heghine Khachatryan: Colombo 2026 Insights on Point-of-Care Ultrasound in Hemophilia Joint Care
-
Sep 8, 2026, 15:57Flora Peyvandi: Efficiency Meets Innovation in Hemophilia B Gene Therapy
-
Sep 8, 2026, 15:48Maxime Dely: Guillain-Barré Syndrome – What if the Key Lies in the Plasma?
-
Sep 8, 2026, 15:34Ron DePinho: A Negative Trial Highlights the Need for Precision in Cardiovascular Inflammation
-
Sep 8, 2026, 15:31Adil Yousaf: Thrombolysis Speed Matters, but Eligibility Comes First
-
Sep 8, 2026, 15:28Dhargam Aljebouri: First Molecularly Characterized Para-Bombay Phenotype in the Arab World
-
Sep 8, 2026, 15:27Mohd Ashhad: How Much Does Hemoglobin Increase After 1 Unit of PRBC?
-
Sep 8, 2026, 15:27Sanish Babu: The Hematocrit–Platelet Signal in Severe Dengue
-
Sep 8, 2026, 15:26Mary Kama: Climate-Informed Early Warning Systems for Sickle Cell Anaemia